Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 10 August →